| |
Total cases (n=200) |
Low expression group (n=100) |
High expression group (n=100) |
p |
| Age (years) |
42.32 ± 10.675 |
40.75 ± 10.240 |
43.90 ± 10.917 |
0.037 |
Sex
Males
Females |
106 (53%)
94 (47%) |
49 (49%)
51 (51%) |
57 (57%)
43 (43%) |
0.257 |
| Fever |
144 (72.0%) |
76 (76%) |
68 (68%) |
0.208 |
|
Infection |
128 (64.0%) |
66 (66%) |
62 (%) |
0.556 |
| Bleeding |
96 (48.0%) |
45 (45%) |
51 (51%) |
0.396 |
| Lymphadenopathy |
112 (56.0%) |
53 (53%) |
59 (59%) |
0.393 |
| Hepatomegaly |
84 (42.0%) |
46 (46%) |
38 (38%) |
0.252 |
| Splenomegaly |
100 (50.0%) |
55 (55%) |
45 (45%) |
0.157 |
| Mediastinal mass |
5 (2.5%) |
2 (2%) |
3 (%) |
0.651 |
| WBC (X109/l) |
55.40 ± 65.670 |
44.50 ± 44.052 |
66.30 ± 80.548 |
0.019 |
| Hb (g/dl) |
9.5676 ± 2.17064 |
9.7754 ± 2.07674 |
9.3598 ± 2.25185 |
0.176 |
| Platelets (X109/l) |
42.79 ± 61.462 |
37.17 ± 51.071 |
48.41 ± 70.150 |
0.197 |
| Peripheral blasts (%) |
53.98 ± 21.502 |
54.75 ± 23.255 |
53.21 ± 19.680 |
0.614 |
| Marrow blasts (%) |
69.44 ± 20.734 |
71.44 ± 19.864 |
67.44 ± 21.483 |
0.173 |
| LDH (u/l) |
1011.4 ± 912.10 |
837.43 ± 635.88788 |
1185.4 ± 1098.53183 |
0.007 |
| Immunophenotype |
|
|
|
|
| CD34 |
133 (66.5%) |
58 (58.0%) |
75 (75.0%) |
0.011 |
| Immunophenotype subtypes |
|
|
|
0.202 |
Pro B ALL
Common B ALL
Pre B ALL |
16 (8.0%) |
7 (7.0%) |
9 (9.0%) |
| 144 (72.0%) |
68 (68.0%) |
76 (76.0%) |
| 40 (20.0%) |
25 (25.0%) |
15 (15.0%) |
| BCR- ABL |
|
|
|
|
Positive
Negative |
67 (33.5%) |
25 (25.0%) |
42 (42.0%) |
0.011 |
| 133 (66.7%) |
75 (75.0%) |
58 (58.0%) |
Age, WBC, Hb, platelats, blasts, LDH and uric acid were presented by mean ± SD. Clinical presentations, immunophenotype and gender were presented by number and percentages. WBC: White Blood Cell Count;Hb: Hemoglobin Concentration; LDH: Lactate Dehydrogenase. |
